Ranimustine
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
methyl 6-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-6-deoxy-α-D-glucopyranoside
|
|
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Legal status |
|
Routes of administration |
IV |
Identifiers | |
CAS Number | 58994-96-0 |
ATC code | L01AD07 (WHO) |
PubChem | CID: 71741 |
ChemSpider | 64785 |
UNII | RYH2T97J77 |
Synonyms | 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea |
Chemical data | |
Formula | C10H18ClN3O7 |
Molecular mass | 327.71 g/mol |
|
|
|
|
(verify) |
Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]
It has never been filed for FDA evaluation in the United States, where it is not marketed.
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
- (Japanese) Cymerin サイメリン (PDF) Mitsubishi Tanabe Pharma. October 2007.
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with reference errors
- Drugs with non-standard legal status
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles with Japanese-language external links
- Alkylating antineoplastic agents
- Nitrosamines
- Ureas
- Nitrosoureas
- Antineoplastic and immunomodulating drug stubs